Clinical Trials Browser

Diffuse Intrinsic Pontine Glioma, Ependymoma, Medulloblastoma, Recurrence

NCT07424092 2026-02-20

PED-DNX2401

Phase 2 Not yet recruiting

39 enrolled

CNS

Ependymoma, Glioma, Recurrence

NCT07390539 2026-02-05

B7-H3.CD28Z.CART in CNS Neoplasms

Phase 1 Not yet recruiting

70 enrolled

CNS

Brain Neoplasms, Ependymoma, Medulloblastoma, Meningeal Neoplasms, Pinealoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT06804655 2025-10-02

EViDENCE-BT

Phase 2 Not yet recruiting

40 enrolled

CNS

Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neoplasms, Neurologic Manifestations

NCT07061626 2025-07-11

Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma

Phase 1 Not yet recruiting

56 enrolled

Ependymoma

NCT06678867 2025-03-27

P5A

Phase 2 Not yet recruiting

80 enrolled

CNS

Brain Neoplasms, Ependymoma, Glioma

NCT06323408 2025-03-25

BZKF-AYA

Not yet recruiting

72 enrolled

CNS

Ependymoma, Glioma, Medulloblastoma, Neoplasms, Germ Cell and Embryonal

NCT06499636 2024-07-12

PBTS23

Not yet recruiting

100 enrolled

CNS

Ependymoma, Glioma, Medulloblastoma

Clinical Trials

PRiME II

PED-DNX2401

B7-H3.CD28Z.CART in CNS Neoplasms

EViDENCE-BT

Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma

P5A

BZKF-AYA

PBTS23